David Smadja 🎗️
@davidmsmadja.bsky.social
Professeur d’Hématologie, Hôpital Europeen Georges Pompidou et Université Paris cité
Inserm PARCC team director « endotheliopathy and Hemostasis disorders »
Association Résiste de lutte contre le harcèlement scolaire et le cyber harcèlement
Inserm PARCC team director « endotheliopathy and Hemostasis disorders »
Association Résiste de lutte contre le harcèlement scolaire et le cyber harcèlement
Reposted by David Smadja 🎗️
🚨 New paper from the lab in ATVB
Dexamethasone protects against COVID-19 endothelium-induced coagulopathy 🦠🔥🫁🩸
@davidmsmadja.bsky.social @hopitalpompidou.bsky.social @upcite.bsky.social @parcc-inserm.bsky.social
@ahajournals.bsky.social
@inserm.fr
www.ahajournals.org/doi/10.1161/...
Dexamethasone protects against COVID-19 endothelium-induced coagulopathy 🦠🔥🫁🩸
@davidmsmadja.bsky.social @hopitalpompidou.bsky.social @upcite.bsky.social @parcc-inserm.bsky.social
@ahajournals.bsky.social
@inserm.fr
www.ahajournals.org/doi/10.1161/...
Dexamethasone Suppresses Endotheliopathy and Endothelial-Induced Coagulopathy in COVID-19 | Arteriosclerosis, Thrombosis, and Vascular Biology
BACKGROUND: Endotheliopathy and coagulopathy are known complications of COVID-19, with a significant
association with mortality. Although dexamethasone is the standard of care for patients
with severe...
www.ahajournals.org
October 2, 2025 at 11:49 AM
🚨 New paper from the lab in ATVB
Dexamethasone protects against COVID-19 endothelium-induced coagulopathy 🦠🔥🫁🩸
@davidmsmadja.bsky.social @hopitalpompidou.bsky.social @upcite.bsky.social @parcc-inserm.bsky.social
@ahajournals.bsky.social
@inserm.fr
www.ahajournals.org/doi/10.1161/...
Dexamethasone protects against COVID-19 endothelium-induced coagulopathy 🦠🔥🫁🩸
@davidmsmadja.bsky.social @hopitalpompidou.bsky.social @upcite.bsky.social @parcc-inserm.bsky.social
@ahajournals.bsky.social
@inserm.fr
www.ahajournals.org/doi/10.1161/...
Reposted by David Smadja 🎗️
Maladie thromboembolique veineuse : prédire le risque de récidive grâce à la génétique
Lire le communiqué : presse.inserm.fr/maladie-thro...
Lire le communiqué : presse.inserm.fr/maladie-thro...
Maladie thromboembolique veineuse : prédire le risque de récidive grâce à la génétique - Salle de presse de l'Inserm
Troisième cause de mortalité cardiovasculaire, la maladie thromboembolique veineuse résulte de la formation d’un caillot pouvant bloquer la circulation sanguine dans une veine et provoquer des complic...
presse.inserm.fr
August 25, 2025 at 1:17 PM
Maladie thromboembolique veineuse : prédire le risque de récidive grâce à la génétique
Lire le communiqué : presse.inserm.fr/maladie-thro...
Lire le communiqué : presse.inserm.fr/maladie-thro...
Reposted by David Smadja 🎗️
PARCC Highlight:
New research from Pr Rosa Maria Bruno @PARCC INSERM and Université Paris Cité, published in the European Heart Journal, reveals that COVID-19 can accelerate vascular aging, especially in women. doi.org/10.1093/eurh...
New research from Pr Rosa Maria Bruno @PARCC INSERM and Université Paris Cité, published in the European Heart Journal, reveals that COVID-19 can accelerate vascular aging, especially in women. doi.org/10.1093/eurh...
Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study
AbstractBackground and Aims. Increasing evidence suggests that COVID-19 survivors experience long-term cardiovascular complications possibly through develo
doi.org
August 21, 2025 at 11:13 AM
PARCC Highlight:
New research from Pr Rosa Maria Bruno @PARCC INSERM and Université Paris Cité, published in the European Heart Journal, reveals that COVID-19 can accelerate vascular aging, especially in women. doi.org/10.1093/eurh...
New research from Pr Rosa Maria Bruno @PARCC INSERM and Université Paris Cité, published in the European Heart Journal, reveals that COVID-19 can accelerate vascular aging, especially in women. doi.org/10.1093/eurh...
Reposted by David Smadja 🎗️
B Tavitian team and coworkers @PARCC used MRI to evaluate myocardial strain and T1 mapping in mice. This methodological approach not only refines imaging sequences but also offers insights into cardiac function and tissue characteristics. www.nature.com/articles/s41...
Left ventricle strain and T1 mapping evaluation in a mouse model with myocardial infarction - Scientific Reports
Scientific Reports - Left ventricle strain and T1 mapping evaluation in a mouse model with myocardial infarction
www.nature.com
August 25, 2025 at 2:28 PM
B Tavitian team and coworkers @PARCC used MRI to evaluate myocardial strain and T1 mapping in mice. This methodological approach not only refines imaging sequences but also offers insights into cardiac function and tissue characteristics. www.nature.com/articles/s41...
Reposted by David Smadja 🎗️
David Smadja and co-workers @PARCC found that the biomarker sST2 independently predict clinical outcomes in hospitalized COVID-19 patients.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial - Scientific Reports
Scientific Reports - sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
www.nature.com
August 25, 2025 at 4:10 PM
David Smadja and co-workers @PARCC found that the biomarker sST2 independently predict clinical outcomes in hospitalized COVID-19 patients.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by David Smadja 🎗️
O. Lenoir, P.L. Tharaux and co-workers @PARCC have developed PathoPlex, a powerful new framework for multiplexed tissue imaging. This scalable tool maps over 140 proteins at subcellular resolution, helping to uncover key disease mechanisms in kidney health and disease.
rdcu.be/eCs2P
rdcu.be/eCs2P
Pathology-oriented multiplexing enables integrative disease mapping
Nature - Pathology-oriented multiplexing (PathoPlex) represents a framework for widespread access to multiplexed imaging and computational image analysis of clinical specimens at a relatively high...
rdcu.be
August 26, 2025 at 9:43 AM
O. Lenoir, P.L. Tharaux and co-workers @PARCC have developed PathoPlex, a powerful new framework for multiplexed tissue imaging. This scalable tool maps over 140 proteins at subcellular resolution, helping to uncover key disease mechanisms in kidney health and disease.
rdcu.be/eCs2P
rdcu.be/eCs2P
Reposted by David Smadja 🎗️
🎉Last paper from the team 📰
Retrospective study of all cases of adverse events (AEs) under #venetoclax recorded in the French pharmacovigilance database 🇫🇷 since its market approval.
➡️ 36% AEs were not listed in the SPC including autoimmune hemolytic anemias (2%) 🩸 or cardiac (7%) ❤️🩹
Retrospective study of all cases of adverse events (AEs) under #venetoclax recorded in the French pharmacovigilance database 🇫🇷 since its market approval.
➡️ 36% AEs were not listed in the SPC including autoimmune hemolytic anemias (2%) 🩸 or cardiac (7%) ❤️🩹
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years - Alexis Talbot, Pierre-Ed...
Background: Venetoclax is the first representative of a new class of targeted therapy, that inhibits selectively B-cell lymphoma-2 (BCL-2), an anti-apoptotic pr...
journals.sagepub.com
August 1, 2025 at 5:59 PM
🎉Last paper from the team 📰
Retrospective study of all cases of adverse events (AEs) under #venetoclax recorded in the French pharmacovigilance database 🇫🇷 since its market approval.
➡️ 36% AEs were not listed in the SPC including autoimmune hemolytic anemias (2%) 🩸 or cardiac (7%) ❤️🩹
Retrospective study of all cases of adverse events (AEs) under #venetoclax recorded in the French pharmacovigilance database 🇫🇷 since its market approval.
➡️ 36% AEs were not listed in the SPC including autoimmune hemolytic anemias (2%) 🩸 or cardiac (7%) ❤️🩹
Entretien dans Marianne : pourquoi la désinformation en santé est un enjeu démocratique.
🎯 Notre objectif : faire de la santé un bien démocratique, fondé sur la confiance, la transparence et le partage du savoir. Il ne s’agit pas de censurer, mais de reconstruire un socle commun de compréhension.
🎯 Notre objectif : faire de la santé un bien démocratique, fondé sur la confiance, la transparence et le partage du savoir. Il ne s’agit pas de censurer, mais de reconstruire un socle commun de compréhension.
July 23, 2025 at 11:25 AM
Entretien dans Marianne : pourquoi la désinformation en santé est un enjeu démocratique.
🎯 Notre objectif : faire de la santé un bien démocratique, fondé sur la confiance, la transparence et le partage du savoir. Il ne s’agit pas de censurer, mais de reconstruire un socle commun de compréhension.
🎯 Notre objectif : faire de la santé un bien démocratique, fondé sur la confiance, la transparence et le partage du savoir. Il ne s’agit pas de censurer, mais de reconstruire un socle commun de compréhension.
Reposted by David Smadja 🎗️
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
->Nature | #Covid19 | More info from EcoSearch
->Nature | #Covid19 | More info from EcoSearch
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
This protocol is based on the protocol produced by the National Institute of Health for the World Health Organization (WHO), version of 03/03/2020, which further led to the Solidarity protocol of WHO. This study supports the integration of the Solidarity...
www.nature.com
April 24, 2025 at 4:27 PM
🧬 🔬 Notre nouveau papier dans Scientific Reports identifie le biomarqueur sST2 comme biomarqueur pour prédire l’évolution clinique COVID-19 dans l’essai #DisCoVeRy 🇪🇺
📖 doi.org/10.1038/s415...
#COVID19 #EUResponse #endotheliopthy #ST2
📖 doi.org/10.1038/s415...
#COVID19 #EUResponse #endotheliopthy #ST2
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial - Scientific Reports
Scientific Reports - sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
doi.org
April 24, 2025 at 5:08 PM
🧬 🔬 Notre nouveau papier dans Scientific Reports identifie le biomarqueur sST2 comme biomarqueur pour prédire l’évolution clinique COVID-19 dans l’essai #DisCoVeRy 🇪🇺
📖 doi.org/10.1038/s415...
#COVID19 #EUResponse #endotheliopthy #ST2
📖 doi.org/10.1038/s415...
#COVID19 #EUResponse #endotheliopthy #ST2
🔎 How can we fight a pandemic when misinformation spreads faster than the virus itself?
📍 Next week, I’ll have the pleasure of speaking at the University of Toronto
🎤 I’ll be sharing my reflections on the topic:
"From Viral Outbreak to Infodemic: The Dual Pandemics of COVID-19"
📍 Next week, I’ll have the pleasure of speaking at the University of Toronto
🎤 I’ll be sharing my reflections on the topic:
"From Viral Outbreak to Infodemic: The Dual Pandemics of COVID-19"
April 19, 2025 at 9:10 PM
🔎 How can we fight a pandemic when misinformation spreads faster than the virus itself?
📍 Next week, I’ll have the pleasure of speaking at the University of Toronto
🎤 I’ll be sharing my reflections on the topic:
"From Viral Outbreak to Infodemic: The Dual Pandemics of COVID-19"
📍 Next week, I’ll have the pleasure of speaking at the University of Toronto
🎤 I’ll be sharing my reflections on the topic:
"From Viral Outbreak to Infodemic: The Dual Pandemics of COVID-19"
Reposted by David Smadja 🎗️
The article published in the @NEJM.org can be accessed.see below
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
April 1, 2025 at 9:53 PM
Reposted by David Smadja 🎗️
The article published in the @NEJM.org can be accessed.see below
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
April 1, 2025 at 2:35 PM
The article published in the @NEJM.org can be accessed.see below
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
🩸 Thrombose & embolie pulmonaire : Bravo @gendronn.bsky.social : les CD34⁺ pourraient prédire séquelles post-EP. Un pas de plus —> meilleure compréhension de la recanalisation du thrombus @upcite.bsky.social @hopitalpompidou.bsky.social
📄 link.springer.com/article/10.1...
📄 link.springer.com/article/10.1...
https://doi.org/10.1007/s12015…
March 16, 2025 at 9:57 AM
🩸 Thrombose & embolie pulmonaire : Bravo @gendronn.bsky.social : les CD34⁺ pourraient prédire séquelles post-EP. Un pas de plus —> meilleure compréhension de la recanalisation du thrombus @upcite.bsky.social @hopitalpompidou.bsky.social
📄 link.springer.com/article/10.1...
📄 link.springer.com/article/10.1...
🚨 Les scientifiques quittent Twitter/X, laissant le terrain aux complotistes. Faut-il fuir ou riposter ?
🔗 Lire notre analyse rédigée avec le professeur @nsonnac.bsky.social
@hopitalpompidou.bsky.social
@upcite.bsky.social
link.springer.com/article/10.1...
🔗 Lire notre analyse rédigée avec le professeur @nsonnac.bsky.social
@hopitalpompidou.bsky.social
@upcite.bsky.social
link.springer.com/article/10.1...
A Highway for Disinformation? The Alarming Exodus of Scientists from Twitter/X and its Consequences - Stem Cell Reviews and Reports
Stem Cell Reviews and Reports -
link.springer.com
March 13, 2025 at 4:06 PM
🚨 Les scientifiques quittent Twitter/X, laissant le terrain aux complotistes. Faut-il fuir ou riposter ?
🔗 Lire notre analyse rédigée avec le professeur @nsonnac.bsky.social
@hopitalpompidou.bsky.social
@upcite.bsky.social
link.springer.com/article/10.1...
🔗 Lire notre analyse rédigée avec le professeur @nsonnac.bsky.social
@hopitalpompidou.bsky.social
@upcite.bsky.social
link.springer.com/article/10.1...
Poste AHU en Pharmacovigilance/Hématologie
La Faculté de Pharmacie de Paris et l'HEGP-PARCC recrutent un AHU en pharmacovigilance et hématologie à partir de novembre 2025.
📩 Contactez le Pr David Smadja : david.smadja@aphp.fr
🔁 RT bienvenus !
#Pharmacovigilance #AHU
@hopitalpompidou.bsky.social
La Faculté de Pharmacie de Paris et l'HEGP-PARCC recrutent un AHU en pharmacovigilance et hématologie à partir de novembre 2025.
📩 Contactez le Pr David Smadja : david.smadja@aphp.fr
🔁 RT bienvenus !
#Pharmacovigilance #AHU
@hopitalpompidou.bsky.social
March 12, 2025 at 1:32 PM
Poste AHU en Pharmacovigilance/Hématologie
La Faculté de Pharmacie de Paris et l'HEGP-PARCC recrutent un AHU en pharmacovigilance et hématologie à partir de novembre 2025.
📩 Contactez le Pr David Smadja : david.smadja@aphp.fr
🔁 RT bienvenus !
#Pharmacovigilance #AHU
@hopitalpompidou.bsky.social
La Faculté de Pharmacie de Paris et l'HEGP-PARCC recrutent un AHU en pharmacovigilance et hématologie à partir de novembre 2025.
📩 Contactez le Pr David Smadja : david.smadja@aphp.fr
🔁 RT bienvenus !
#Pharmacovigilance #AHU
@hopitalpompidou.bsky.social
🚨 Nouvelle revue de notre équipe publiée dans Angiogenesis et ses nouvelles perspectives en médecine régénérative en image 👇🩸🧪✅
link.springer.com/article/10.1...
link.springer.com/article/10.1...
March 11, 2025 at 4:38 PM
🚨 Nouvelle revue de notre équipe publiée dans Angiogenesis et ses nouvelles perspectives en médecine régénérative en image 👇🩸🧪✅
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Reposted by David Smadja 🎗️
The #VTE risk associated with #JAKi in #inflammatory diseases has been suggested, followed by precautionary measures by health authorities. This literature review illustrates that available data on VTE risk on JAKi are conflicting and inconclusive
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...
February 26, 2025 at 12:28 PM
The #VTE risk associated with #JAKi in #inflammatory diseases has been suggested, followed by precautionary measures by health authorities. This literature review illustrates that available data on VTE risk on JAKi are conflicting and inconclusive
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...
Reposted by David Smadja 🎗️
Regulatory agencies have issued warnings about JAK inhibitors and VTE risk—but what does the evidence actually say?
Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social
📑 Read now: buff.ly/4ijJQNq
Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social
📑 Read now: buff.ly/4ijJQNq
March 2, 2025 at 8:55 AM
Regulatory agencies have issued warnings about JAK inhibitors and VTE risk—but what does the evidence actually say?
Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social
📑 Read now: buff.ly/4ijJQNq
Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social
📑 Read now: buff.ly/4ijJQNq
Reposted by David Smadja 🎗️
Very happy to be part of this international collaboration 🇨🇦🇫🇷🇪🇸🇳🇿🇩🇪 defining the VITT-like Monoclonal Gammopathy of Thrombotic Significance @nejm.org
@hopitalpompidou.bsky.social
@hopitalcochin.bsky.social
@upcite.bsky.social
www.nejm.org/doi/full/10....
#VITT #AntiPF4 #Thrombosis
@hopitalpompidou.bsky.social
@hopitalcochin.bsky.social
@upcite.bsky.social
www.nejm.org/doi/full/10....
#VITT #AntiPF4 #Thrombosis
VITT-like Monoclonal Gammopathy of Thrombotic Significance | NEJM
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is associated with antibodies that target platelet factor 4 (PF4) and are heparin-independent. VITT antibodies are implicated in acute,...
www.nejm.org
February 13, 2025 at 2:02 PM
Very happy to be part of this international collaboration 🇨🇦🇫🇷🇪🇸🇳🇿🇩🇪 defining the VITT-like Monoclonal Gammopathy of Thrombotic Significance @nejm.org
@hopitalpompidou.bsky.social
@hopitalcochin.bsky.social
@upcite.bsky.social
www.nejm.org/doi/full/10....
#VITT #AntiPF4 #Thrombosis
@hopitalpompidou.bsky.social
@hopitalcochin.bsky.social
@upcite.bsky.social
www.nejm.org/doi/full/10....
#VITT #AntiPF4 #Thrombosis
Reposted by David Smadja 🎗️
Découvrez en vidéo la nouvelle chaîne robotisée de biologie de l'Hôpital européen Georges-Pompidou @ap-hp.bsky.social !
Un espace entièrement modernisé avec une plateforme automatisée regroupant de nombreuses innovations en robotique.
👉 youtu.be/M8BaWTES0H8
Un espace entièrement modernisé avec une plateforme automatisée regroupant de nombreuses innovations en robotique.
👉 youtu.be/M8BaWTES0H8
Laboratoire de biologie médicale : une chaîne entièrement robotisée au service des patients à l'HEGP
YouTube video by AP-HP, Assistance Publique - Hôpitaux de Paris
youtu.be
February 12, 2025 at 6:39 PM
Découvrez en vidéo la nouvelle chaîne robotisée de biologie de l'Hôpital européen Georges-Pompidou @ap-hp.bsky.social !
Un espace entièrement modernisé avec une plateforme automatisée regroupant de nombreuses innovations en robotique.
👉 youtu.be/M8BaWTES0H8
Un espace entièrement modernisé avec une plateforme automatisée regroupant de nombreuses innovations en robotique.
👉 youtu.be/M8BaWTES0H8
Reposted by David Smadja 🎗️
🥳 New findings from our group on anti-PF4/H antibodies during #COVID19 and post #vaccination ! #HIT #VITT @rpth.bsky.social 📰
🔗 www.rpthjournal.org/article/S247...
@davidmsmadja.bsky.social @terrierben.bsky.social
@upcite.bsky.social @hopitalpompidou.bsky.social
🔗 www.rpthjournal.org/article/S247...
@davidmsmadja.bsky.social @terrierben.bsky.social
@upcite.bsky.social @hopitalpompidou.bsky.social
Relevance of anti-PF4/H antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic
The increased interest in anti-platelet factor 4 (PF4)-heparin complex (anti-PF4/H)
antibodies following the COVID-19 pandemic has established them as crucial players
in immunothrombosis. We aimed to ...
www.rpthjournal.org
February 9, 2025 at 5:15 PM
🥳 New findings from our group on anti-PF4/H antibodies during #COVID19 and post #vaccination ! #HIT #VITT @rpth.bsky.social 📰
🔗 www.rpthjournal.org/article/S247...
@davidmsmadja.bsky.social @terrierben.bsky.social
@upcite.bsky.social @hopitalpompidou.bsky.social
🔗 www.rpthjournal.org/article/S247...
@davidmsmadja.bsky.social @terrierben.bsky.social
@upcite.bsky.social @hopitalpompidou.bsky.social
@lesechosfr.bsky.social parlent de notre projet de peau artificielle pre-vascularisée ⭐️⭐️⭐️ #pepr #inserm
www.lesechos.fr/idees-debats...
www.lesechos.fr/idees-debats...
www.lesechos.fr
January 21, 2025 at 3:11 PM
@lesechosfr.bsky.social parlent de notre projet de peau artificielle pre-vascularisée ⭐️⭐️⭐️ #pepr #inserm
www.lesechos.fr/idees-debats...
www.lesechos.fr/idees-debats...
Reposted by David Smadja 🎗️
La grippe, une maladie mortelle surtout après 65 ans.
L'année dernière 54% des plus de 65 ans se sont fait vacciner.
3 000 vies supplémentaires pourraient être sauvées si la couverture vaccinale était supérieure à 75 % après 65 ans (seuil fixé par l’OMS).
source : www.ameli.fr/paris/medeci...
L'année dernière 54% des plus de 65 ans se sont fait vacciner.
3 000 vies supplémentaires pourraient être sauvées si la couverture vaccinale était supérieure à 75 % après 65 ans (seuil fixé par l’OMS).
source : www.ameli.fr/paris/medeci...
January 17, 2025 at 6:00 PM
La grippe, une maladie mortelle surtout après 65 ans.
L'année dernière 54% des plus de 65 ans se sont fait vacciner.
3 000 vies supplémentaires pourraient être sauvées si la couverture vaccinale était supérieure à 75 % après 65 ans (seuil fixé par l’OMS).
source : www.ameli.fr/paris/medeci...
L'année dernière 54% des plus de 65 ans se sont fait vacciner.
3 000 vies supplémentaires pourraient être sauvées si la couverture vaccinale était supérieure à 75 % après 65 ans (seuil fixé par l’OMS).
source : www.ameli.fr/paris/medeci...
Reposted by David Smadja 🎗️
On the heightened risk of autoimmune diseases after Covid erictopol.substack.com/p/the-height...
The heightened risk of autoimmune diseases after Covid
Facts, data, and analytics about biomedical matters.
erictopol.substack.com
January 3, 2025 at 4:54 PM
On the heightened risk of autoimmune diseases after Covid erictopol.substack.com/p/the-height...